HEALTH● LOWAug 19 · Aug 19, 2026, 12:54 PM
Teva gets FDA priority review for Tourette syndrome therapy
Seeking Alpha Tech
Teva Pharmaceuticals has received priority review status from the FDA for its new therapy designed to treat Tourette syndrome, potentially accelerating its approval process.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH46m agoCaffeine pouches are trapping children in a 'vicious cycle' - and their use can be hard to detectThe Independent WorldHEALTH1h agoKarnataka to set up committee to boost deceased donor organ transplantsThe HinduHEALTH1h agoKarnataka to frame policy against hospitals withholding bodies over unpaid billsThe HinduHEALTH1h agoUnitedHealthcare, Humana Medicare Advantage cancellations to affect 1 millionThe Hill